Pharma & Biotech Mergers & Acquisitions News
Biotechnology
Texan pre-clinical stage biotech CrossBridge Bio, a developer of dual-payload antibody-drug conjugates (ADCs), has announced a definitive agreement to be acquired by US pharma major Eli Lilly. 14 April 2026
Today's issue
Refine search
Latest Mergers & Acquisitions News & Features
Biotechnology
US clinical-stage biotechnology company Beeline Medicines today announced its official debut with the mission of developing and delivering category-leading precision therapies to transform the lives of people with autoimmune and inflammatory diseases. 15 April 2026
Pharmaceutical
India’s Rubicon Research today announced the acquisition of an 85% equity ownership in Arinna Lifesciences from its current shareholders. 15 April 2026
Biotechnology
USA-based Galera Therapeutics and Obsidian Therapeutics, a privately-held clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocyte (TIL) cell therapies, announced that they have entered into a definitive merger agreement to combine in an all-stock transaction. 15 April 2026
Biotechnology
Texan pre-clinical stage biotech CrossBridge Bio, a developer of dual-payload antibody-drug conjugates (ADCs), has announced a definitive agreement to be acquired by US pharma major Eli Lilly. 14 April 2026
Generics
The Russian drugmaker Binnopharm Group, which was founded by the local billionaire Vladimir Yevtushenkov, hopes to acquire Akrikhin, the local drugmaker, which is owned by the Polish-Dutch company Polpharma and which produces some important and best selling drugs in the Russian market. 14 April 2026
Biotechnology
Important news last week kicked off with Neurocrine Biosciences announcing a proposed $2.9 billion takeover bid for Solena Therapeutics. Then Gilead Sciences revealed an up to $5 billion takeover for German antibody-drug conjugate (ADCs) developer Tubulis. Also of note, Sanofi released mixed Phase II results for its asthma and dermatology candidate lunsekimig. The US Food and Drug Administration (FDA) announced plans for greater control of direct-to-consumer Rx medicines advertising. 12 April 2026
Pharmaceutical
Illinois, USA-based Assertio Holdings yesterday announced a definitive agreement to be acquired by Garda Therapeutics for $18 per share in cash, or a total cash consideration of $125.1 million, plus a contingent value right (CVR). 9 April 2026
Biotechnology
US biotech major Gilead Sciences is to acquire Tubulis, a privately-held German biotech developing next-generation antibody-drug conjugates (ADCs). 7 April 2026
Biotechnology
US drugmakers Neurocrine Biosciences and Soleno Therapeutics on Monday announced they entered into a definitive agreement for the former to acquire Soleno for $53.00 per share in cash, representing a total transaction equity value of $2.9 billion. Soleno’ shares rose 33.5% to $52.70 on the news. 7 April 2026
Pharmaceutical
Important research news last week included US pharma giant Merck & Co moving its Winrevair into Phase III for pulmonary arterial hypertension. On the M&A front, Biogen announced a $5.6 billion takeover for Apellis and its two main products – Empaveli and Syfovre. Eli Lilly’s oral obesity drug orforglipron has been granted US Food and Drug Administration (FDA) in a record time, under the trade name Foundayo. Also of note, Sino-American biotech Adagene struck a deal with the USA’s Incyte to evaluate muzastotug in colorectal cancer. 5 April 2026
Pharmaceutical
India-headquartered Lupin Limited revealed the completion of its acquisition of VISUfarma, a European specialty pharmaceutical company focused on ophthalmology, from GHO Capital Partners LLP (GHO). 2 April 2026
Pharmaceutical
March marked a clear acceleration in biopharma M&A, with activity shifting toward larger, strategically significant deals alongside continued bolt-on acquisitions. 1 April 2026
Biotechnology
Cyclerion Therapeutics’ shares more than doubled in Wednesday’s pre-market trade, rallying nearly 200% to $1.55 after the company announced a merger deal with privately-held Korsana Biosciences 1 April 2026
Pharmaceutical
Shares of US clinical-stage drug developer Centessa Pharmaceuticals leapt 44% to $39.72 on the news that it has reached a definitive agreement for US pharma major Eli Lilly to acquire the company. 1 April 2026
Biotechnology
Apellis Pharmaceuticals saw its shares leap 136% to $40.47 in pre-market activity today, on the announcement of an agreement to be acquired by US biotech major Biogen. 31 March 2026
Biotechnology
Kezar Life Sciences shares jumped about 21% to $7.45 by close on Monday after Aurinia Pharmaceuticals announced an agreement to acquire the company for $6.955 per share in cash plus a contingent value right (CVR). 31 March 2026
Pharmaceutical
Last week’s significant research news included Pfizer and French partner Valneva releasing mixed data on their much-anticipated Phase III trial of Lyme disease vaccine candidate LB6V/VLA15. Also, Insmed announced top-line Phase IIIb data for its lung disease candidate Arikayce and regulatory filing plans. Among M&A news, Gilead Sciences announced a $2 billion+ deal to acquire Ouro Medicines and its TCE inhibitor gamgertamig, while Merck & Co revealed a takeover bid for Terns Pharmaceuticals and its leukemia candidate TERN-701. 29 March 2026
Pharmaceutical
Japan’s Otsuka Pharmaceutical is to buy US firm Transcend Therapeutics for $700 million upfront and up to $525 million in milestones, for a total potential consideration of $1.225 billion. 27 March 2026
Biotechnology
The company formerly known as Vaxess Technologies has announced a rebrand and is now calling itself Terrestrial Bio. 27 March 2026
Biotechnology
Swiss pharma giant Novartis today announced that it has entered into an agreement to acquire Excellergy, a private biotech company developing next-generation anti-IgE therapies for IgE-driven diseases. 27 March 2026
Biotechnology
US clinical-stage biotechnology company Beeline Medicines today announced its official debut with the mission of developing and delivering category-leading precision therapies to transform the lives of people with autoimmune and inflammatory diseases. 15 April 2026
Pharmaceutical
India’s Rubicon Research today announced the acquisition of an 85% equity ownership in Arinna Lifesciences from its current shareholders. 15 April 2026
Biotechnology
USA-based Galera Therapeutics and Obsidian Therapeutics, a privately-held clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocyte (TIL) cell therapies, announced that they have entered into a definitive merger agreement to combine in an all-stock transaction. 15 April 2026
Biotechnology
Texan pre-clinical stage biotech CrossBridge Bio, a developer of dual-payload antibody-drug conjugates (ADCs), has announced a definitive agreement to be acquired by US pharma major Eli Lilly. 14 April 2026
Generics
The Russian drugmaker Binnopharm Group, which was founded by the local billionaire Vladimir Yevtushenkov, hopes to acquire Akrikhin, the local drugmaker, which is owned by the Polish-Dutch company Polpharma and which produces some important and best selling drugs in the Russian market. 14 April 2026
Biotechnology
Important news last week kicked off with Neurocrine Biosciences announcing a proposed $2.9 billion takeover bid for Solena Therapeutics. Then Gilead Sciences revealed an up to $5 billion takeover for German antibody-drug conjugate (ADCs) developer Tubulis. Also of note, Sanofi released mixed Phase II results for its asthma and dermatology candidate lunsekimig. The US Food and Drug Administration (FDA) announced plans for greater control of direct-to-consumer Rx medicines advertising. 12 April 2026
Pharmaceutical
Illinois, USA-based Assertio Holdings yesterday announced a definitive agreement to be acquired by Garda Therapeutics for $18 per share in cash, or a total cash consideration of $125.1 million, plus a contingent value right (CVR). 9 April 2026
Biotechnology
US biotech major Gilead Sciences is to acquire Tubulis, a privately-held German biotech developing next-generation antibody-drug conjugates (ADCs). 7 April 2026
Biotechnology
US drugmakers Neurocrine Biosciences and Soleno Therapeutics on Monday announced they entered into a definitive agreement for the former to acquire Soleno for $53.00 per share in cash, representing a total transaction equity value of $2.9 billion. Soleno’ shares rose 33.5% to $52.70 on the news. 7 April 2026
Pharmaceutical
Important research news last week included US pharma giant Merck & Co moving its Winrevair into Phase III for pulmonary arterial hypertension. On the M&A front, Biogen announced a $5.6 billion takeover for Apellis and its two main products – Empaveli and Syfovre. Eli Lilly’s oral obesity drug orforglipron has been granted US Food and Drug Administration (FDA) in a record time, under the trade name Foundayo. Also of note, Sino-American biotech Adagene struck a deal with the USA’s Incyte to evaluate muzastotug in colorectal cancer. 5 April 2026
Pharmaceutical
India-headquartered Lupin Limited revealed the completion of its acquisition of VISUfarma, a European specialty pharmaceutical company focused on ophthalmology, from GHO Capital Partners LLP (GHO). 2 April 2026
Pharmaceutical
March marked a clear acceleration in biopharma M&A, with activity shifting toward larger, strategically significant deals alongside continued bolt-on acquisitions. 1 April 2026
Biotechnology
Cyclerion Therapeutics’ shares more than doubled in Wednesday’s pre-market trade, rallying nearly 200% to $1.55 after the company announced a merger deal with privately-held Korsana Biosciences 1 April 2026
Pharmaceutical
Shares of US clinical-stage drug developer Centessa Pharmaceuticals leapt 44% to $39.72 on the news that it has reached a definitive agreement for US pharma major Eli Lilly to acquire the company. 1 April 2026
Biotechnology
Apellis Pharmaceuticals saw its shares leap 136% to $40.47 in pre-market activity today, on the announcement of an agreement to be acquired by US biotech major Biogen. 31 March 2026
Biotechnology
Kezar Life Sciences shares jumped about 21% to $7.45 by close on Monday after Aurinia Pharmaceuticals announced an agreement to acquire the company for $6.955 per share in cash plus a contingent value right (CVR). 31 March 2026
Pharmaceutical
Last week’s significant research news included Pfizer and French partner Valneva releasing mixed data on their much-anticipated Phase III trial of Lyme disease vaccine candidate LB6V/VLA15. Also, Insmed announced top-line Phase IIIb data for its lung disease candidate Arikayce and regulatory filing plans. Among M&A news, Gilead Sciences announced a $2 billion+ deal to acquire Ouro Medicines and its TCE inhibitor gamgertamig, while Merck & Co revealed a takeover bid for Terns Pharmaceuticals and its leukemia candidate TERN-701. 29 March 2026
Pharmaceutical
Japan’s Otsuka Pharmaceutical is to buy US firm Transcend Therapeutics for $700 million upfront and up to $525 million in milestones, for a total potential consideration of $1.225 billion. 27 March 2026
Biotechnology
The company formerly known as Vaxess Technologies has announced a rebrand and is now calling itself Terrestrial Bio. 27 March 2026
Biotechnology
Swiss pharma giant Novartis today announced that it has entered into an agreement to acquire Excellergy, a private biotech company developing next-generation anti-IgE therapies for IgE-driven diseases. 27 March 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze